Global Mouse Model for Drug Screening and Evaluation Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Mouse Model for Drug Screening and Evaluation: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Mouse Model for Drug Screening and Evaluation Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Tumor Model
1.2.3 Nervous System Model
1.2.4 Immunodeficiency
1.2.5 Metabolic and Cardiovascular Disease Model
1.2.6 Digestive System Model
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Mouse Model for Drug Screening and Evaluation Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Research Laboratories
1.3.3 Pharmaceutical Companies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Mouse Model for Drug Screening and Evaluation Revenue Estimates and Forecasts 2020-2031
2.2 Global Mouse Model for Drug Screening and Evaluation Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Mouse Model for Drug Screening and Evaluation Sales Estimates and Forecasts 2020-2031
2.4 Global Mouse Model for Drug Screening and Evaluation Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Mouse Model for Drug Screening and Evaluation Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Mouse Model for Drug Screening and Evaluation Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Tumor Model Market Size by Manufacturers
3.5.2 Nervous System Model Market Size by Manufacturers
3.5.3 Immunodeficiency Market Size by Manufacturers
3.5.4 Metabolic and Cardiovascular Disease Model Market Size by Manufacturers
3.5.5 Digestive System Model Market Size by Manufacturers
3.5.6 Others Market Size by Manufacturers
3.6 Global Mouse Model for Drug Screening and Evaluation Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Mouse Model for Drug Screening and Evaluation Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Mouse Model for Drug Screening and Evaluation Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Mouse Model for Drug Screening and Evaluation Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Mouse Model for Drug Screening and Evaluation Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Mouse Model for Drug Screening and Evaluation Sales and Revenue by Type (2020-2031)
6.4 North America Mouse Model for Drug Screening and Evaluation Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Mouse Model for Drug Screening and Evaluation Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Mouse Model for Drug Screening and Evaluation Sales and Revenue by Type (2020-2031)
7.4 Europe Mouse Model for Drug Screening and Evaluation Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Mouse Model for Drug Screening and Evaluation Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Mouse Model for Drug Screening and Evaluation Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Mouse Model for Drug Screening and Evaluation Sales and Revenue by Type (2020-2031)
9.4 Central and South America Mouse Model for Drug Screening and Evaluation Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Mouse Model for Drug Screening and Evaluation Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Mouse Model for Drug Screening and Evaluation Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Mouse Model for Drug Screening and Evaluation Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Mouse Model for Drug Screening and Evaluation Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 ingenious targeting laboratory
11.1.1 ingenious targeting laboratory Corporation Information
11.1.2 ingenious targeting laboratory Business Overview
11.1.3 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.1.4 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation Sales by Product in 2024
11.1.6 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation Sales by Application in 2024
11.1.7 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation Sales by Geographic Area in 2024
11.1.8 ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation SWOT Analysis
11.1.9 ingenious targeting laboratory Recent Developments
11.2 The Jackson Laboratory
11.2.1 The Jackson Laboratory Corporation Information
11.2.2 The Jackson Laboratory Business Overview
11.2.3 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.2.4 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation Sales by Product in 2024
11.2.6 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation Sales by Application in 2024
11.2.7 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation Sales by Geographic Area in 2024
11.2.8 The Jackson Laboratory Mouse Model for Drug Screening and Evaluation SWOT Analysis
11.2.9 The Jackson Laboratory Recent Developments
11.3 Charles River
11.3.1 Charles River Corporation Information
11.3.2 Charles River Business Overview
11.3.3 Charles River Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.3.4 Charles River Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Charles River Mouse Model for Drug Screening and Evaluation Sales by Product in 2024
11.3.6 Charles River Mouse Model for Drug Screening and Evaluation Sales by Application in 2024
11.3.7 Charles River Mouse Model for Drug Screening and Evaluation Sales by Geographic Area in 2024
11.3.8 Charles River Mouse Model for Drug Screening and Evaluation SWOT Analysis
11.3.9 Charles River Recent Developments
11.4 Taconic Biosciences
11.4.1 Taconic Biosciences Corporation Information
11.4.2 Taconic Biosciences Business Overview
11.4.3 Taconic Biosciences Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.4.4 Taconic Biosciences Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Taconic Biosciences Mouse Model for Drug Screening and Evaluation Sales by Product in 2024
11.4.6 Taconic Biosciences Mouse Model for Drug Screening and Evaluation Sales by Application in 2024
11.4.7 Taconic Biosciences Mouse Model for Drug Screening and Evaluation Sales by Geographic Area in 2024
11.4.8 Taconic Biosciences Mouse Model for Drug Screening and Evaluation SWOT Analysis
11.4.9 Taconic Biosciences Recent Developments
11.5 Cavens
11.5.1 Cavens Corporation Information
11.5.2 Cavens Business Overview
11.5.3 Cavens Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.5.4 Cavens Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Cavens Mouse Model for Drug Screening and Evaluation Sales by Product in 2024
11.5.6 Cavens Mouse Model for Drug Screening and Evaluation Sales by Application in 2024
11.5.7 Cavens Mouse Model for Drug Screening and Evaluation Sales by Geographic Area in 2024
11.5.8 Cavens Mouse Model for Drug Screening and Evaluation SWOT Analysis
11.5.9 Cavens Recent Developments
11.6 Beijing Vitalstar Biotechnology
11.6.1 Beijing Vitalstar Biotechnology Corporation Information
11.6.2 Beijing Vitalstar Biotechnology Business Overview
11.6.3 Beijing Vitalstar Biotechnology Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.6.4 Beijing Vitalstar Biotechnology Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Beijing Vitalstar Biotechnology Recent Developments
11.7 Model Organisms Center
11.7.1 Model Organisms Center Corporation Information
11.7.2 Model Organisms Center Business Overview
11.7.3 Model Organisms Center Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.7.4 Model Organisms Center Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Model Organisms Center Recent Developments
11.8 GENET-MED
11.8.1 GENET-MED Corporation Information
11.8.2 GENET-MED Business Overview
11.8.3 GENET-MED Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.8.4 GENET-MED Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 GENET-MED Recent Developments
11.9 Cyagen
11.9.1 Cyagen Corporation Information
11.9.2 Cyagen Business Overview
11.9.3 Cyagen Mouse Model for Drug Screening and Evaluation Product Models, Descriptions and Specifications
11.9.4 Cyagen Mouse Model for Drug Screening and Evaluation Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Cyagen Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Mouse Model for Drug Screening and Evaluation Industry Chain
12.2 Mouse Model for Drug Screening and Evaluation Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Mouse Model for Drug Screening and Evaluation Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Mouse Model for Drug Screening and Evaluation Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Mouse Model for Drug Screening and Evaluation Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Mouse Model for Drug Screening and Evaluation Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Mouse Model for Drug Screening and Evaluation Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Mouse Model for Drug Screening and Evaluation Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Mouse Model for Drug Screening and Evaluation Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Mouse Model for Drug Screening and Evaluation Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Mouse Model for Drug Screening and Evaluation Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Unit)
Table 7. Global Mouse Model for Drug Screening and Evaluation Sales by Region (2020-2025) & (Unit)
Table 8. Global Mouse Model for Drug Screening and Evaluation Sales by Region (2026-2031) & (Unit)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Mouse Model for Drug Screening and Evaluation Sales by Manufacturers (2020-2025) & (Unit)
Table 11. Global Mouse Model for Drug Screening and Evaluation Sales Share by Manufacturers (2020-2025)
Table 12. Global Mouse Model for Drug Screening and Evaluation Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Mouse Model for Drug Screening and Evaluation Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Mouse Model for Drug Screening and Evaluation by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mouse Model for Drug Screening and Evaluation as of 2024)
Table 16. Global Mouse Model for Drug Screening and Evaluation Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Mouse Model for Drug Screening and Evaluation Average Selling Price (ASP) by Manufacturers (2020-2025) & (USD/Unit)
Table 18. Key Manufacturers Mouse Model for Drug Screening and Evaluation Manufacturing Base and Headquarters
Table 19. Global Mouse Model for Drug Screening and Evaluation Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Mouse Model for Drug Screening and Evaluation Sales by Type (2020-2025) & (Unit)
Table 23. Global Mouse Model for Drug Screening and Evaluation Sales by Type (2026-2031) & (Unit)
Table 24. Global Mouse Model for Drug Screening and Evaluation Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Mouse Model for Drug Screening and Evaluation Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Mouse Model for Drug Screening and Evaluation ASP by Type (2020-2031) & (USD/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Mouse Model for Drug Screening and Evaluation Sales by Application (2020-2025) & (Unit)
Table 29. Global Mouse Model for Drug Screening and Evaluation Sales by Application (2026-2031) & (Unit)
Table 30. Mouse Model for Drug Screening and Evaluation High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Mouse Model for Drug Screening and Evaluation Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Mouse Model for Drug Screening and Evaluation Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Mouse Model for Drug Screening and Evaluation ASP by Application (2020-2031) & (USD/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Mouse Model for Drug Screening and Evaluation Growth Accelerators and Market Barriers
Table 37. North America Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Mouse Model for Drug Screening and Evaluation Sales (Unit) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Mouse Model for Drug Screening and Evaluation Growth Accelerators and Market Barriers
Table 40. Europe Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Mouse Model for Drug Screening and Evaluation Sales (Unit) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales (Unit) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Mouse Model for Drug Screening and Evaluation Growth Accelerators and Market Barriers
Table 45. Southeast Asia Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Mouse Model for Drug Screening and Evaluation Investment Opportunities and Key Challenges
Table 47. Central and South America Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Mouse Model for Drug Screening and Evaluation Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Mouse Model for Drug Screening and Evaluation Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. ingenious targeting laboratory Corporation Information
Table 51. ingenious targeting laboratory Description and Major Businesses
Table 52. ingenious targeting laboratory Product Models, Descriptions and Specifications
Table 53. ingenious targeting laboratory Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 54. ingenious targeting laboratory Sales Value Proportion by Product in 2024
Table 55. ingenious targeting laboratory Sales Value Proportion by Application in 2024
Table 56. ingenious targeting laboratory Sales Value Proportion by Geographic Area in 2024
Table 57. ingenious targeting laboratory Mouse Model for Drug Screening and Evaluation SWOT Analysis
Table 58. ingenious targeting laboratory Recent Developments
Table 59. The Jackson Laboratory Corporation Information
Table 60. The Jackson Laboratory Description and Major Businesses
Table 61. The Jackson Laboratory Product Models, Descriptions and Specifications
Table 62. The Jackson Laboratory Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 63. The Jackson Laboratory Sales Value Proportion by Product in 2024
Table 64. The Jackson Laboratory Sales Value Proportion by Application in 2024
Table 65. The Jackson Laboratory Sales Value Proportion by Geographic Area in 2024
Table 66. The Jackson Laboratory Mouse Model for Drug Screening and Evaluation SWOT Analysis
Table 67. The Jackson Laboratory Recent Developments
Table 68. Charles River Corporation Information
Table 69. Charles River Description and Major Businesses
Table 70. Charles River Product Models, Descriptions and Specifications
Table 71. Charles River Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Charles River Sales Value Proportion by Product in 2024
Table 73. Charles River Sales Value Proportion by Application in 2024
Table 74. Charles River Sales Value Proportion by Geographic Area in 2024
Table 75. Charles River Mouse Model for Drug Screening and Evaluation SWOT Analysis
Table 76. Charles River Recent Developments
Table 77. Taconic Biosciences Corporation Information
Table 78. Taconic Biosciences Description and Major Businesses
Table 79. Taconic Biosciences Product Models, Descriptions and Specifications
Table 80. Taconic Biosciences Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Taconic Biosciences Sales Value Proportion by Product in 2024
Table 82. Taconic Biosciences Sales Value Proportion by Application in 2024
Table 83. Taconic Biosciences Sales Value Proportion by Geographic Area in 2024
Table 84. Taconic Biosciences Mouse Model for Drug Screening and Evaluation SWOT Analysis
Table 85. Taconic Biosciences Recent Developments
Table 86. Cavens Corporation Information
Table 87. Cavens Description and Major Businesses
Table 88. Cavens Product Models, Descriptions and Specifications
Table 89. Cavens Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Cavens Sales Value Proportion by Product in 2024
Table 91. Cavens Sales Value Proportion by Application in 2024
Table 92. Cavens Sales Value Proportion by Geographic Area in 2024
Table 93. Cavens Mouse Model for Drug Screening and Evaluation SWOT Analysis
Table 94. Cavens Recent Developments
Table 95. Beijing Vitalstar Biotechnology Corporation Information
Table 96. Beijing Vitalstar Biotechnology Description and Major Businesses
Table 97. Beijing Vitalstar Biotechnology Product Models, Descriptions and Specifications
Table 98. Beijing Vitalstar Biotechnology Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 99. Beijing Vitalstar Biotechnology Recent Developments
Table 100. Model Organisms Center Corporation Information
Table 101. Model Organisms Center Description and Major Businesses
Table 102. Model Organisms Center Product Models, Descriptions and Specifications
Table 103. Model Organisms Center Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. Model Organisms Center Recent Developments
Table 105. GENET-MED Corporation Information
Table 106. GENET-MED Description and Major Businesses
Table 107. GENET-MED Product Models, Descriptions and Specifications
Table 108. GENET-MED Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 109. GENET-MED Recent Developments
Table 110. Cyagen Corporation Information
Table 111. Cyagen Description and Major Businesses
Table 112. Cyagen Product Models, Descriptions and Specifications
Table 113. Cyagen Sales (Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 114. Cyagen Recent Developments
Table 115. Key Raw Materials Distribution
Table 116. Raw Materials Key Suppliers
Table 117. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 118. Milestones in Production Technology Evolution
Table 119. Distributors List
Table 120. Market Trends and Market Evolution
Table 121. Market Drivers and Opportunities
Table 122. Market Challenges, Risks, and Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources


List of Figures
Figure 1. Mouse Model for Drug Screening and Evaluation Product Picture
Figure 2. Global Mouse Model for Drug Screening and Evaluation Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Tumor Model Product Picture
Figure 4. Nervous System Model Product Picture
Figure 5. Immunodeficiency Product Picture
Figure 6. Metabolic and Cardiovascular Disease Model Product Picture
Figure 7. Digestive System Model Product Picture
Figure 8. Others Product Picture
Figure 9. Global Mouse Model for Drug Screening and Evaluation Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Research Laboratories
Figure 11. Pharmaceutical Companies
Figure 12. Other
Figure 13. Mouse Model for Drug Screening and Evaluation Report Years Considered
Figure 14. Global Mouse Model for Drug Screening and Evaluation Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 16. Global Mouse Model for Drug Screening and Evaluation Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Mouse Model for Drug Screening and Evaluation Revenue Market Share by Region (2020-2031)
Figure 18. Global Mouse Model for Drug Screening and Evaluation Sales (2020-2031) & (Unit)
Figure 19. Global Mouse Model for Drug Screening and Evaluation Sales (CAGR) by Region (2020-2031) (Unit)
Figure 20. Global Mouse Model for Drug Screening and Evaluation Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Volume Market Share in 2024
Figure 22. Global Mouse Model for Drug Screening and Evaluation Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Tumor Model Revenue Market Share by Manufacturer in 2024
Figure 25. Nervous System Model Revenue Market Share by Manufacturer in 2024
Figure 26. Immunodeficiency Revenue Market Share by Manufacturer in 2024
Figure 27. Metabolic and Cardiovascular Disease Model Revenue Market Share by Manufacturer in 2024
Figure 28. Digestive System Model Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Mouse Model for Drug Screening and Evaluation Sales Market Share by Type (2020-2031)
Figure 31. Global Mouse Model for Drug Screening and Evaluation Revenue Market Share by Type (2020-2031)
Figure 32. Global Mouse Model for Drug Screening and Evaluation Sales Market Share by Application (2020-2031)
Figure 33. Global Mouse Model for Drug Screening and Evaluation Revenue Market Share by Application (2020-2031)
Figure 34. North America Mouse Model for Drug Screening and Evaluation Sales YoY (2020-2031) & (Unit)
Figure 35. North America Mouse Model for Drug Screening and Evaluation Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) in 2024
Figure 37. North America Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Type (2020- 2031)
Figure 38. North America Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Application (2020-2031)
Figure 40. North America Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Mouse Model for Drug Screening and Evaluation Sales YoY (2020-2031) & (Unit)
Figure 45. Europe Mouse Model for Drug Screening and Evaluation Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) in 2024
Figure 47. Europe Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Type (2020-2031)
Figure 48. Europe Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Application (2020-2031)
Figure 50. Europe Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 52. France Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales YoY (2020-2031) & (Unit)
Figure 57. Asia-Pacific Mouse Model for Drug Screening and Evaluation Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Type (2020- 2031)
Figure 60. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Application (2020-2031)
Figure 62. Asia-Pacific Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 67. India Mouse Model for Drug Screening and Evaluation Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Mouse Model for Drug Screening and Evaluation Sales YoY (2020-2031) & (Unit)
Figure 69. Central and South America Mouse Model for Drug Screening and Evaluation Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Type (2021-2031)
Figure 72. Central and South America Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Application (2020-2031)
Figure 74. Central and South America Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Mouse Model for Drug Screening and Evaluation Sales YoY (2020-2031) & (Unit)
Figure 78. Middle East and Africa Mouse Model for Drug Screening and Evaluation Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Type (2021-2031)
Figure 81. South America Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Mouse Model for Drug Screening and Evaluation Sales Volume (Unit) by Application (2020-2031)
Figure 83. Middle East and Africa Mouse Model for Drug Screening and Evaluation Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Mouse Model for Drug Screening and Evaluation Revenue (2020-2025) & (US$ Million)
Figure 88. Mouse Model for Drug Screening and Evaluation Industry Chain Mapping
Figure 89. Regional Mouse Model for Drug Screening and Evaluation Manufacturing Base Distribution (%)
Figure 90. Global Mouse Model for Drug Screening and Evaluation Production Market Share by Region (2020-2031)
Figure 91. Mouse Model for Drug Screening and Evaluation Production Process
Figure 92. Regional Mouse Model for Drug Screening and Evaluation Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit